{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:29:32Z","timestamp":1793734172829,"version":"4.6.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:00:00Z","timestamp":1715472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:00:00Z","timestamp":1715472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cell- and antibody-based CD19-directed therapies have demonstrated great potential for treating B-cell non-Hodgkin lymphoma (B-NHL). However, all these approaches suffer from limited response rates and considerable toxicity. Until now, therapy decisions have been routinely based on histopathological CD19 staining of a single lesion at initial diagnosis or relapse, disregarding heterogeneity and temporal alterations in antigen expression. To visualize in vivo CD19 expression noninvasively, we radiolabeled anti-human CD19 monoclonal antibodies with copper-64 (<jats:sup>64<\/jats:sup>Cu-\u03b1CD19) for positron emission tomography (CD19-immunoPET). <jats:sup>64<\/jats:sup>Cu-\u03b1CD19 specifically bound to subcutaneous Daudi xenograft mouse models in vivo. Importantly, <jats:sup>64<\/jats:sup>Cu-\u03b1CD19 did not affect the anti-lymphoma cytotoxicity of CD19 CAR-T cells in vitro. Following our preclinical validation, <jats:sup>64<\/jats:sup>Cu-\u03b1CD19 was injected into four patients with follicular lymphoma, diffuse large B-cell lymphoma or mantle zone lymphoma. We observed varying <jats:sup>64<\/jats:sup>Cu-\u03b1CD19 PET uptake patterns at different lymphoma sites, both within and among patients, correlating with ex vivo immunohistochemical CD19 expression. Moreover, one patient exhibited enhanced uptake in the spleen compared to that in patients with prior B-cell-depleting therapy, indicating that <jats:sup>64<\/jats:sup>Cu-\u03b1CD19 is applicable for identifying B-cell-rich organs. In conclusion, we demonstrated the specific targeting and visualization of CD19<jats:sup>+<\/jats:sup> B-NHL in mice and humans by CD19-immunoPET. The intra- and interindividual heterogeneous <jats:sup>64<\/jats:sup>Cu-\u03b1CD19 uptake patterns of lymphoma lesions indicate variability in CD19 expression, suggesting the potential of CD19-immunoPET as a novel tool to guide CD19-directed therapies.<\/jats:p>","DOI":"10.1186\/s40364-024-00595-9","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T13:01:38Z","timestamp":1715518898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7085-0161","authenticated-orcid":false,"given":"Dominik","family":"Sonanini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schwenck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Blaess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ehrlichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Skokowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Kneilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundram","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falko","family":"Fend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Krost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Reischl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Handgretinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian la","family":"Foug\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd J.","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,12]]},"reference":[{"issue":"5","key":"595_CR1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/CCO.0000000000000671","volume":"32","author":"A Salaroli","year":"2020","unstructured":"Salaroli A, Spilleboudt C, Bron D, Lewalle P. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions. Curr Opin Oncol. 2020;32(5):434\u201341.","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"595_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus Lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978\u201388.","journal-title":"Lancet Oncol"},{"issue":"11","key":"595_CR3","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410\u20136.","journal-title":"Blood"},{"issue":"6","key":"595_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Reviews Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"6","key":"595_CR5","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790\u2013800.","journal-title":"Lancet Oncol"},{"issue":"Supplement1","key":"595_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood-2019-127683","volume":"134","author":"DJ Reiss","year":"2019","unstructured":"Reiss DJ, Do T, Kuo D, Gray VE, Olson NE, Lee C-W, et al. Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with Relapsed\/Refractory (R\/R) diffuse large B cell lymphoma (DLBCL) treated with Lisocabtagene Maraleucel (liso-cel) in Transcend NHL 001 reveal patterns of Immune Infiltration Associated with durable response. Blood. 2019;134(Supplement1):202.","journal-title":"Blood"},{"issue":"15suppl","key":"595_CR7","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/JCO.2017.35.15_suppl.3025","volume":"35","author":"J Galon","year":"2017","unstructured":"Galon J, Rossi J, Turcan S, Danan C, Locke FL, Neelapu SS, et al. Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19). J Clin Oncol. 2017;35(15suppl):3025.","journal-title":"J Clin Oncol"},{"issue":"22","key":"595_CR8","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1182\/blood.V128.22.2941.2941","volume":"128","author":"BJC Villasboas","year":"2016","unstructured":"Villasboas BJC, Ansell S. Heterogeneity of the Tumor Microenvirontment in diffuse large B-Cell lymphoma revealed by deep phenotyping using Mass Cytometry (CyTOF). Blood. 2016;128(22):2941.","journal-title":"Blood"},{"issue":"10","key":"595_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor Antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219.","journal-title":"Cancer Discov"},{"issue":"7","key":"595_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","volume":"23","author":"J Schwenck","year":"2023","unstructured":"Schwenck J, Sonanini D, Cotton JM, Rammensee HG, la Foug\u00e8re C, Zender L, Pichler BJ. Advances in PET imaging of cancer. Nat Rev Cancer. 2023;23(7):474\u201390.","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"595_CR11","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.7150\/thno.56736","volume":"12","author":"J Schmitt","year":"2022","unstructured":"Schmitt J, Schwenck J, Maurer A, Przybille M, Sonanini D, Reischl G, et al. Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma. Theranostics. 2022;12(13):5615\u201330.","journal-title":"Theranostics"},{"issue":"3","key":"595_CR12","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.7150\/thno.92481","volume":"14","author":"NF Trautwein","year":"2024","unstructured":"Trautwein NF, Schwenck J, Seitz C, Seith F, Calder\u00f3n E, von Beschwitz S, et al. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [(64)Cu]Cu-NOTA-ch14.18\/CHO. Theranostics. 2024;14(3):1212\u201323.","journal-title":"Theranostics"},{"issue":"1","key":"595_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12974-020-01880-8","volume":"17","author":"MY Stevens","year":"2020","unstructured":"Stevens MY, Cropper HC, Lucot KL, Chaney AM, Lechtenberg KJ, Jackson IM, et al. Development of a CD19 PET tracer for detecting B cells in a mouse model of multiple sclerosis. J Neuroinflammation. 2020;17(1):275.","journal-title":"J Neuroinflammation"},{"issue":"7791","key":"595_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549\u201355.","journal-title":"Nature"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-024-00595-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-024-00595-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-024-00595-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T13:08:06Z","timestamp":1715519286000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-024-00595-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,12]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1186\/s40364-024-00595-9","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,12]]},"assertion":[{"value":"8 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects provided written consent according to national regulations and the Declaration of Helsinki. The evaluation of patient data was approved by the ethics committee of the University of T\u00fcbingen (533\/2021BO2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed on the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that no conflicts of interest exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}